X-Chem earned a milestone payment from Relay Therapeutics (RLAY). This followed Relay's initiation of a Phase 3 clinical trial for zovegalisib (RLY-2608). The breast cancer drug candidate originated from a compound identified using X-Chem's DNA-encoded chemical library (DEL) screening technology.
The collaboration discovered a novel inhibitor for the oncology target phosphoinositide 3-kinase alpha (PI3Kα). Relay Therapeutics advanced this initial compound into zovegalisib's development. The late-stage trial's commencement marks a key step in the clinical development of a drug from the partnership's early discovery efforts.